STABILIZED AND EXTENDED RELEASE FORMATION OF SARPOGRELATE

摘要

PURPOSE: An extended release formulation containing sarpogrelate or pharmaceutically acceptable salt thereof as a pharmacologically active ingredient is provided to ensure an equal treatment effect with an immediate release tablet which is administered three times a day, and to enable long-term storage with stability. CONSTITUTION: An extended release formulation contains sarpogrelate or pharmaceutically acceptable salt thereof as a pharmacologically acceptable ingredient. The formulation contains 10-50 wt% of one or more hydrophilic polymers selected among hydroxypropyl methyl cellulose, polyethylene oxide, or carbomer. The formulation additionally contains one or more stabilizing agents selected among citric acid, anhydrous citric acid, succinic acid, L-gluamic acid, L-malic acid, boric acid, tartaric acid, lactic acid, or furmaric acid. The formulation also contains one or more lubricants among stearic acid, magnesium stearate, talc, and colloidal silicon dioxide. The pharmaceutically acceptable salt is hydrochloride. [Reference numerals] (AA) Elution rate(%); (BB) Comparative example 3; (CC) Example 2-12; (DD) Time(hr)